• 中国精品科技期刊
  • 《中文核心期刊要目总览》收录期刊
  • RCCSE 中国核心期刊(5/114,A+)
  • Scopus收录期刊
  • 美国《化学文摘》(CA)收录期刊
  • WHO 西太平洋地区医学索引(WPRIM)收录期刊
  • 《中国科学引文数据库(CSCD)》核心库期刊 (C)
  • 中国科技核心期刊
  • 中国科技论文统计源期刊
  • 《日本科学技术振兴机构数据库(中国)》(JSTChina)收录期刊
  • 美国《乌利希期刊指南》(UIrichsweb)收录期刊
  • 中华预防医学会系列杂志优秀期刊(2019年)

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

广东省东莞市30~79岁居民代谢相关脂肪性肝病患病现状

杨嘉璐, 罗燕芳, 单忍湖, 左志刚, 余振, 陈武农, 朱耀文, 李柳清, 骆诗韵, 叶咏欣, 张卓宇, 李瑞, 巨竞萌, 朱姗姗, 范佳画, 夏敏. 广东省东莞市30~79岁居民代谢相关脂肪性肝病患病现状[J]. 中华疾病控制杂志, 2021, 25(10): 1175-1179, 1230. doi: 10.16462/j.cnki.zhjbkz.2021.10.011
引用本文: 杨嘉璐, 罗燕芳, 单忍湖, 左志刚, 余振, 陈武农, 朱耀文, 李柳清, 骆诗韵, 叶咏欣, 张卓宇, 李瑞, 巨竞萌, 朱姗姗, 范佳画, 夏敏. 广东省东莞市30~79岁居民代谢相关脂肪性肝病患病现状[J]. 中华疾病控制杂志, 2021, 25(10): 1175-1179, 1230. doi: 10.16462/j.cnki.zhjbkz.2021.10.011
YANG Jia-lu, LUO Yan-fang, SHAN Ren-hu, ZUO Zhi-gang, YU Zhen, CHEN Wu-nong, ZHU Yao-wen, LI Liu-qing, LUO Shi-yun, YE Yong-xin, ZHANG Zhuo-yu, LI Rui, JU Jing-meng, ZHU Shan-shan, FAN Jia-hua, XIA Min. The prevalence of the metabolic associated fatty liver disease among residents aged 30 to 79 in Dongguan City of Guangdong Province[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2021, 25(10): 1175-1179, 1230. doi: 10.16462/j.cnki.zhjbkz.2021.10.011
Citation: YANG Jia-lu, LUO Yan-fang, SHAN Ren-hu, ZUO Zhi-gang, YU Zhen, CHEN Wu-nong, ZHU Yao-wen, LI Liu-qing, LUO Shi-yun, YE Yong-xin, ZHANG Zhuo-yu, LI Rui, JU Jing-meng, ZHU Shan-shan, FAN Jia-hua, XIA Min. The prevalence of the metabolic associated fatty liver disease among residents aged 30 to 79 in Dongguan City of Guangdong Province[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2021, 25(10): 1175-1179, 1230. doi: 10.16462/j.cnki.zhjbkz.2021.10.011

广东省东莞市30~79岁居民代谢相关脂肪性肝病患病现状

doi: 10.16462/j.cnki.zhjbkz.2021.10.011
基金项目: 

国家重点研发计划 2017YFC0907100

详细信息
    通讯作者:

    夏敏,E-mail: xiamin@mail.sysu.edu.cn

  • 中图分类号: R181.2

The prevalence of the metabolic associated fatty liver disease among residents aged 30 to 79 in Dongguan City of Guangdong Province

Funds: 

National Key Research and Development Program of China 2017YFC0907100

More Information
  • 摘要:   目的  了解广东省东莞市30~79岁居民代谢相关脂肪性肝病(metabolic associated fatty liver disease, MAFLD) 的患病情况,探讨不同人群特征对MAFLD患病的影响。  方法  利用华南区域自然人群慢性病前瞻性队列研究在广东省东莞市的基线调查数据,包括体格检查、腹部超声检查和临床检验,共纳入8 670名研究对象。参考国际专家小组共识声明判断MAFLD患病情况。采用多因素Logistic回归分析模型分析男、女性MAFLD患病的影响因素。  结果  东莞市30~79岁居民MAFLD患病率为31.85%。男性各年龄段MAFLD患病率的差异无统计学意义(χ2 =2.958, P=0.565),女性患病率随年龄的增加而呈线性增长的趋势(χ趋势2=81.429, P<0.001)。MAFLD患病率随BMI、FPG、ALT、TG、TC、血尿酸(uric acid, UA)等代谢指标的升高而升高,随HDL-C的升高而降低。多因素Logistic回归分析模型结果显示年龄≥50岁的女性患MAFLD风险较高(OR=2.37, 95% CI: 1.74~3.23, P<0.001)。  结论  东莞市30~79岁居民MAFLD患病率为31.85%,与BMI、FPG、TG、TC等代谢指标之间呈线性关联。年龄≥50岁可能是女性患MAFLD的危险因素。
  • 图  1  2018―2019年广东省东莞市不同特征调查对象的MAFLD患病率

    Figure  1.  The prevalence of MAFLD according to various characteristics among participants in Dongguan City, Guangdong Province from 2018 to 2019

    表  1  2018―2019年广东省东莞市30~79岁调查对象的基本特征[n(%)]

    Table  1.   Basic characteristics of participants aged 30 to 79 in Dongguan City, Guangdong Province from 2018 to 2019 [n(%)]

    变量 总人群(N=8 670) 男性(n=3 525) 女性(n=5 145) t/t’/Z/χ2 P
    年龄[(x±s), 岁] 65.33±9.34 65.55±9.42 65.18±9.28 -1.847 0.065
    高血压 4.436 0.035
      有 3 947(46.07) 1 551(44.70) 2 396(47.01)
      无 4 620(53.93) 1 919(55.30) 2 701(52.99)
    超重/肥胖 0.144 0.705
      是 5 498(63.41) 2 227(63.18) 3 271(63.58)
      否 3 172(36.59) 1 298(36.82) 1 874(36.42)
    糖尿病 2.075 0.150
      是 686(8.10) 296(8.62) 390(7.75)
      无 7 783(91.90) 3 139(91.38) 4 644(92.25)
    代谢功能失调 369.934 <0.001
      是 5 618(64.80) 1 864(52.88) 3 754(72.96)
      否 3 052(35.20) 1 661(47.12) 1 391(27.04)
    WC[(x±s), cm] 85.49±9.48 86.55±9.09 84.76±9.68 -8.704 <0.001
    BMI[(x±s), kg/m2] 24.30±3.47 24.11±3.21 24.42±3.63 4.108 <0.001
    SBP[(x±s), mm Hg] 137.31±19.35 136.19±18.13 138.07±20.11 4.499 <0.001
    DBP[(x±s), mm Hg] 81.05±10.66 81.96±10.72 80.43±10.57 -6.537 <0.001
    FPG[M(P25, P75), mmol/L] 4.98(4.57, 5.57) 4.99(4.57, 5.59) 4.97(4.57, 5.56) -0.855 0.393
    ALT[M(P25, P75), IU/L] 20.00(15.00, 26.10) 21.00(16.00, 28.00) 19.00(14.90, 25.00) -10.882 <0.001
    AST[M(P25, P75), IU/L] 22.00(18.80, 26.31) 22.00(19.00, 27.00) 22.00(18.43, 26.00) -3.710 <0.001
    TBIL[M(P25, P75), μmol/L] 13.20(10.60, 16.59) 14.20(11.20, 17.80) 12.70(10.20, 15.70) -14.094 <0.001
    TG[M(P25, P75), mmol/L] 1.38(0.99, 2.02) 1.33(0.94, 1.93) 1.43(1.02, 2.06) -5.909 <0.001
    TC[(x±s), mmol/L] 5.28±1.08 5.04±1.04 5.45±1.07 17.330 <0.001
    HDL-C[(x±s), mmol/L] 1.37±0.34 1.27±0.32 1.43±0.33 23.190 <0.001
    LDL-C[(x±s), mmol/L] 3.26±0.92 3.16±0.90 3.32±0.93 8.264 <0.001
    血尿素[M(P25, P75), mmol/L] 5.44(4.57, 6.51) 5.57(4.67, 6.67) 5.37(4.51, 6.40) -6.590 <0.001
    血肌酐[M(P25, P75), μmol/L] 72.00(61.00, 85.00) 85.00(75.00, 97.00) 64.00(56.90, 73.00) -54.159 <0.001
    UA[(x±s), μmol/L] 364.69±98.50 401.51±96.88 339.53±91.43 -29.510 <0.001
    下载: 导出CSV

    表  2  2018―2019年广东省东莞市不同性别、年龄调查对象MAFLD患病率

    Table  2.   The prevalence of MAFLD according to gender and age group among participants in Dongguan City, Guangdong Province from 2018 to 2019

    年龄组(岁) 性别 总人数 患病人数 患病率(%) χ2 P
    30~<40 91 25 27.47 6.484 0.011
    131 18 13.74
    40~<50 225 66 29.33 20.797 <0.001
    337 46 13.65
    50~<60 286 77 26.92 0.207 0.649
    398 101 25.38
    60~<70 1 620 448 27.65 65.079 <0.001
    2 584 1 030 39.86
    70~79 1 303 329 25.25 44.133 <0.001
    1 695 621 36.64
    下载: 导出CSV

    表  3  2018―2019年广东省东莞市男、女性MAFLD患病的多因素Logistic回归分析

    Table  3.   Multivariate Logistic regression for MAFLD according to gender among participants in Dongguan City, Guangdong Province from 2018 to 2019

    自变量 男性 女性
    β OR(95% CI)值 P β OR(95% CI)值 P
    年龄≥50(岁) 0.218 1.24(0.92~1.69) 0.161 0.862 2.37(1.74~3.23) <0.001
    超重/肥胖 1.750 5.75(4.28~7.34) <0.001 1.547 4.70(3.86~5.71) <0.001
    糖尿病 0.815 2.26(1.70~3.01) <0.001 0.784 2.19(1.71~2.81) <0.001
    WC异常 0.952 2.59(2.15~3.13) <0.001 0.897 2.45(1.98~3.04) <0.001
    血压异常 0.223 1.25(1.02~1.54) 0.035 0.207 1.23(1.04~1.45) 0.013
    TG异常 0.871 2.39(1.99~2.87) <0.001 0.925 2.52(2.18~2.92) <0.001
    HDL-C异常 0.075 1.08(0.88~1.33) 0.477 0.346 1.41(1.22~1.63) <0.001
    ALT异常 0.655 1.93(1.17~3.17) 0.010 0.960 2.61(1.98~3.44) <0.001
    高尿酸血症 0.341 1.41(1.18~1.68) <0.001 0.537 1.71(1.49~1.97) <0.001
    下载: 导出CSV
  • [1] Nan Y, An J, Bao J, et al. The Chinese Society of Hepatology position statement on the redefinition of fatty liver disease[J]. J Hepatol, 2021, 75(2): 454-461. DOI: 10.1016/j.jhep.2021.05.003.
    [2] Zhou F, Zhou J, Wang W, et al. Unexpected rapid increase in the burden of NAFLD in China from 2008 to 2018: a systematic review and meta-analysis[J]. Hepatology, 2019, 70(4): 1119-1133. DOI: 10.1002/hep.30702.
    [3] Eslam M, Sanyal AJ, George J. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease[J]. Gastroenterology, 2020, 158(7): 1999-2014. DOI: 10.1053/j.gastro.2019.11.312.
    [4] Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement[J]. J Hepatol, 2020, 73(1): 202-209. DOI: 10.1016/j.jhep.2020.03.039.
    [5] Xian YX, Weng JP, Xu F. MAFLD vs. NAFLD: shared features and potential changes in epidemiology, pathophysiology, diagnosis, and pharmacotherapy[J]. Chin Med J (Engl), 2020, 134(1): 8-19. DOI: 10.1097/CM9.0000000000001263.
    [6] Nabi O, Lacombe K, Boursier J, et al. Prevalence and risk factors of nonalcoholic fatty liver disease and advanced fibrosis in general population: the French Nationwide NASH-CO Study[J]. Gastroenterology, 2020, 159(2): 791-793. DOI: 10.1053/j.gastro.2020.04.048.
    [7] Eguchi Y, Hyogo H, Ono M, et al. Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: a multicenter large retrospective study[J]. J Gastroenterol, 2012, 47(5): 586-595. DOI: 10.1007/s00535-012-0533-z.
    [8] Huang TD, Behary J, Zekry A. Non-alcoholic fatty liver disease: a review of epidemiology, risk factors, diagnosis and management[J]. Intern Med J, 2020, 50(9): 1038-1047. DOI: 10.1111/imj.14709.
    [9] Chen YL, Li H, Li S, et al. Prevalence of and risk factors for metabolic associated fatty liver disease in an urban population in China: a cross-sectional comparative study[J]. BMC Gastroenterol, 2021, 21(1): 212. DOI: 10.1186/s12876-021-01782-w.
    [10] Li H, Guo M, An Z, et al. Prevalence and risk factors of metabolic associated fatty liver disease in Xinxiang, China[J]. Int J Environ Res Public Health, 2020, 17(6): 1818. DOI: 10.3390/ijerph17061818.
    [11] Liu D, Shen Y, Zhang R, et al. Prevalence and risk factors of metabolic associated fatty liver disease among people living with HIV in China[J]. J Gastroenterol Hepatol, 2020, 36(6): 1670-1678. DOI: 10.1111/jgh.15320.
    [12] Eguchi Y, Hyogo H, Ono M, et al. Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: a multicenter large retrospective study[J]. J Gastroenterol, 2012, 47(5): 586-595. DOI: 10.1007/s00535-012-0533-z.
    [13] Lai X, Yang L, Legare S, et al. Dose-response relationship between serum uric acid levels and risk of incident coronary heart disease in the Dongfeng-Tongji Cohort[J]. Int J Cardiol, 2016, 224: 299-304. DOI: 10.1016/j.ijcard.2016.09.035.
    [14] Wong WV, Wong GL, Woo J, et al. Impact of the new definition of metabolic associated fatty liver disease on the epidemiology of the disease[J]. Clin Gastroenterol Hepatol, 2021, 19(10): 2161-2171. DOI: 10.1016/j.cgh.2020.10.046.
    [15] Zhou YJ, Li YY, Nie YQ, et al. Prevalence of fatty liver disease and its risk factors in the population of South China[J]. World J Gastroenterol, 2007, 13(47): 6419-6424. DOI: 10.3748/wjg.v13.i47.6419.
    [16] Wong VW, Chu WC, Wong GL, et al. Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using proton-magnetic resonance spectroscopy and transient elastography[J]. Gut, 2012, 61(3): 409-415. DOI: 10.1136/gutjnl-2011-300342.
    [17] Park SH, Jeon WK, Kim SH, et al. Prevalence and risk factors of non-alcoholic fatty liver disease among Korean adults[J]. J Gastroenterol Hepatol, 2006, 21(1 Pt 1): 138-143. DOI: 10.1111/j.1440-1746.2005.04086.x.
    [18] Yoneda M, Thomas E, Sumida Y, et al. The influence of menopause on the development of hepatic fibrosis in nonobese women with nonalcoholic fatty liver disease[J]. Hepatology, 2014, 60(5): 1792. DOI: 10.1002/hep.27097.
    [19] Yang JD, Abdelmalek MF, Pang H, et al. Gender and menopause impact severity of fibrosis among patients with nonalcoholic steatohepatitis[J]. Hepatology, 2014, 59(4): 1406-1414. DOI: 10.1002/hep.26761.
    [20] Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American association for the study of liver diseases[J]. Hepatology, 2018, 67(1): 328-357. DOI: 10.1002/hep.29367.
    [21] Dietrich P, Hellerbrand C. Non-alcoholic fatty liver disease, obesity and the metabolic syndrome[J]. Best Pract Res Clin Gastroenterol, 2014, 28(4): 637-653. DOI: 10.1016/j.bpg.2014.07.008.
    [22] Mantovani A, Byrne CD, Bonora E, et al. Nonalcoholic fatty liver disease and risk of incident type 2 diabetes: a meta-analysis[J]. Diabetes Care, 2018, 41(2): 372-382. DOI: 10.2337/dc17-1902.
  • 加载中
图(1) / 表(3)
计量
  • 文章访问数:  8
  • HTML全文浏览量:  0
  • PDF下载量:  5
  • 被引次数: 0
出版历程
  • 收稿日期:  2021-06-07
  • 修回日期:  2021-09-15
  • 网络出版日期:  2021-11-17
  • 刊出日期:  2021-10-10

目录

    /

    返回文章
    返回